Dismantling airway disease with the use of new pulmonary function indices.

We are currently limited in our abilities to diagnose, monitor disease status and manage chronic airway disease like asthma and chronic obstructive pulmonary disease (COPD). Conventional lung function measures often poorly reflect patient symptoms or are insensitive to changes, particularly in the small airways where disease may originate or manifest. Novel pulmonary function tests are becoming available which help us better characterise and understand chronic airway disease, and their translation and adoption from the research arena would potentially enable individualised patient care.In this article, we aim to describe two emerging lung function tests yielding novel pulmonary function indices, the forced oscillation technique (FOT) and multiple breath nitrogen washout (MBNW). With a particular focus on asthma and COPD, this article demonstrates how chronic airway disease mechanisms have been dismantled with the use of the FOT and MBNW. We describe their ability to assess detailed pulmonary mechanics for diagnostic and management purposes including response to bronchodilation and other treatments, relationship with symptoms, evaluation of acute exacerbations and recovery, and telemonitoring. The current limitations of both tests, as well as open questions/directions for further research, are also discussed.
Competing Interests: Conflict of interest: S.C. Zimmermann has nothing to disclose. Conflict of interest: K.O. Tonga has nothing to disclose. Conflict of interest: C. Thamrin has a patent (WO 2006130922 A1) issued and intellectual property arrangements with two FOT device companies, Thorasys Medical Systems and Restech srl relating to scientific collaborations, but does not have any financial relationships with either company.
(Copyright ©ERS 2019.)